Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of MT-0169 in CD38+ Acute Leukemia
NCT06522373Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2024
- Primary completion
- Oct 2024
- Modality
- Immunotoxins, Fc-Fusion Proteins
01
Overview
Phase 1, open-label trial of MT-0169 in acute myeloid leukemia (AML), T cell acute lymphoblastic leukemia (T-ALL), myelodysplastic syndrome (MDS) and 1 more (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events. Planned start Oct 2024; status: withdrawn.
02
Drugs
MT-0169
03
Conditions
acute myeloid leukemia (AML)T cell acute lymphoblastic leukemia (T-ALL)myelodysplastic syndrome (MDS)biphenotypic acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT06522373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06522373.